Leflunomide Sandoz Ltd

Leflunomide, the active ingredient in Leflunomide Sandoz Ltd, is an immunomodulatory agent presented as a tablet for oral use. It is prescribed to manage rheumatoid arthritis and psoriatic arthritis in adult patients.

GNH USA supplies Leflunomide Sandoz Ltd as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Leflunomide is a disease‑modifying antirheumatic drug that acts on inflammatory pathways in autoimmune arthritis.

- Rheumatoid arthritis: reduces disease activity and slows joint damage. - Psoriatic arthritis: improves skin and joint symptoms while inhibiting disease progression. - Inadequate response to other DMARDs: provides an alternative therapeutic option for patients who have not responded sufficiently to first‑line treatments.

Leflunomide may cause a range of adverse reactions.

Common Side Effects: - Diarrhoea: mild to moderate gastrointestinal upset. - Nausea and vomiting: transient, often improves with food. - Alopecia: reversible hair thinning. - Rash: non‑specific skin eruptions. - Headache: occasional, usually mild. - Hypertension: new‑onset or worsening blood pressure.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or severe liver injury. - Severe infections: opportunistic or bacterial infections requiring medical attention. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: life‑threatening skin reactions. - Bone‑marrow suppression: pancytopenia or severe neutropenia. - Interstitial lung disease: respiratory symptoms with imaging changes. - Severe hypertension or hypertensive crisis.

Before initiating therapy, clinicians should evaluate baseline organ function and counsel patients on risk mitigation.

- Liver monitoring: obtain baseline liver function tests and repeat periodically. - Blood pressure: measure regularly and manage hypertension as needed. - Hematology: monitor complete blood count for signs of bone‑marrow suppression. - Hepatic impairment: avoid use in patients with severe liver disease. - Pregnancy: contraindicated; ensure effective contraception throughout treatment and for several months after discontinuation. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Leflunomide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect and risk of bleeding. - Statins (e.g., simvastatin): heightened risk of hepatotoxicity. - Azathioprine or other myelosuppressants: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Methotrexate: combined hepatotoxic potential; monitor liver enzymes. - Antihypertensive agents: possible reduction in blood‑pressure control. - Oral contraceptives: decreased efficacy, consider alternative contraception.